RET/MET/BRAF: initial treatment, acquired resistance, Q&A Joshua Sabari, MD Joshua Bauml, MD

Article and Video CATEGORIES

Cancer Journey

ABOUT

Joshua Bauml, MD, Advisory Board Member, GRACE Faculty

Assistant Professor of Medicine, Hospital of the University of Pennsylvania, and the Veteran’s Administration Medical Center

RET/MET/BRAF: initial treatment, acquired resistance, Q&A Joshua Sabari, MD Joshua Bauml, MD

dbrock

Mon, 10/12/2020 - 17:26

Author

Joshua Bauml, MD, Advisory Board Member, GRACE Faculty

From the Targeted Therapies Patient Forum 2019, Dr. Joshua Bauml and Dr. Joshua Sabari discuss RET, MET and BRAF, the initial treatment and acquired resistance.

To join the conversation, visit https://cancergrace.org/forum.

Video Language

English

Please feel free to offer comments and raise questions in our
discussion forums.

Join The conversation

Next Previous link

Previous Post Next Post

Article

The article describes the AVO treatment, a combination therapy for Chronic Lymphocytic Leukemia (CLL), particularly for high-risk patients. CLL is a slow-growing cancer where abnormal white blood cells accumulate. "High-risk" CLL refers to cases with specific genetic changes (e.g., in TP53) that make the disease harder to treat.